Dapasmart
Dapagliflozin tablets for type 2 diabetes and heart failure. It lowers blood sugar by letting the kidneys remove extra glucose in urine.
- Category
- Diabetes Management
- Active ingredient
- Dapagliflozin
- Route
- Oral use
- Form
- Tablet
- Strengths
- 5mg · 10mg
Prescription and consultation requirements for Dapasmart vary by destination and are determined by the fulfilment partner.
Dapasmart details
- Conditions
- Type 2 Diabetes Mellitus · Heart Failure · Chronic Kidney Disease
- Alternative names
- dapagliflozin
- Therapeutic class
- Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
- Pharmacological class
- SGLT2 Inhibitor
- Contraindications
- severe renal impairment (for glycaemic control); diabetic ketoacidosis
- Minor side effects
- increased urination; nausea
- Moderate side effects
- urinary tract infection; vulvovaginal candidiasis; dyslipidaemia
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Healing Pharma India Pvt Ltd
- Onset Time
- 1–2 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 30°C.
- Drug interactions
- Insulin; Diuretics
- Age restrictions
- Approved for adults.
- Pregnancy and breastfeeding
- Pregnancy: Avoid in second and third trimesters. Breastfeeding: Not recommended.
Serious side effects
diabetic ketoacidosis, requires immediate medical attention; fournier's gangrene, requires immediate medical attention
Patient summary
Dapagliflozin tablets for type 2 diabetes and heart failure. It lowers blood sugar by letting the kidneys remove extra glucose in urine.
Mechanism of action
Blocks SGLT2 in renal tubules, lowering renal glucose reabsorption threshold to promote glucose loss in urine.